Carlyle to sell up to 10% stake in Piramal Pharma, Moneycontrol reports
03/07/2025 12:26
July 3 (Reuters) - U.S. private equity firm Carlyle Group CG.O is preparing to offload up to a 10% stake in India's Piramal Pharma PIRM.NS through block trades, online news portal Moneycontrol reported on Thursday, citing sources. The U.S.-based private equity firm could earn in the range of 26 billion rupees ($304.8 million) to 27 billion rupees from the sale, the report added. ($1 = 85.3090 Indian rupees) (Reporting by Hritam Mukherjee in Bengaluru; Editing by Nivedita Bhattacharjee) ((Hritam.Mukherjee@thomsonreuters.com; X: @MukherjeeHritam;))
Recent news on Piramal Pharma (Mumbai)
See all newsBrief: Piramal Pharma (Mumbai) Says Commercial Arrangement With Bayer Pharmaceuticals To Expire On December 31, 2026
Brief: Piramal Pharma (Mumbai) Says Tax Authority Confirms Demand Of 40.6 Million Rupees And Imposes Equivalent Penalty
India's Piramal Pharma falls after US FDA observations at UK facility
Brief: Piramal Pharma Says US FDA Issues Form-483 With 7 Observations To Morpeth UK Facility
Brief: Piramal Pharma Approves Exercise Of Call Option For Acquisition Of Additional 41% Equity In Yapan Bio